João Nani

Mr. João Nani

Universidade Federal de São Paulo
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
LTLjubica Tasic
Ljubica Tasic
ALAcioly L.T. Larcerda
Acioly L.T. Larcerda
JPJoão G.M. Pontes
João G.M. Pontes
Tássia Brena CostaTássia Brena Costa
Tássia Brena Costa
JNJoão Nani
João Nani
MHMirian Hayashi
Mirian Hayashi

1 July 2019 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
MPMariana Pedrini
Mariana Pedrini
BCBing Cao
Bing Cao
JNJoão Nani
João Nani
RCRaphael O. Cerqueira
Raphael O. Cerqueira
RMRodrigo B. Mansur
Rodrigo B. Mansur
EBElisa Brietzke
Elisa Brietzke

1 January 2020 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
BRBenjamín Rodríguez
Benjamín Rodríguez
JNJoão Nani
João Nani
PAPriscila G.C. Almeida
Priscila G.C. Almeida
EBElisa Brietzke
Elisa Brietzke
Richard S. LeeRichard S. Lee
Richard S. Lee
MHMirian Hayashi
Mirian Hayashi

26 February 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Banny CorreiaBanny Correia
Banny Correia
JNJoão Nani
João Nani
RRRaniery Waladares Ricardo
Raniery Waladares Ricardo
DSDanijela Stanisic
Danijela Stanisic
Tássia Brena CostaTássia Brena Costa
Tássia Brena Costa
LTLjubica Tasic
Ljubica Tasic
Schizophrenia (SCZ) treatment is essentially limited to the use of typical or atypical antipsychotic drugs, which suppress the main symptoms of this mental disorder. Metabolic syndrome is often reported in patients with SCZ under long-term drug treatment, but little is known about the alteration of lipid metabolism induced by antipsychotic use. In this study, we evaluated the blood serum lipids of a validated animal model for SCZ (Spontaneously Hypertensive Rat, SHR), and a normal control rat strain (Normotensive Wistar Rat, NWR), after long-term treatment (30 days) with typical haloperidol (HAL) or atypical clozapine (CLZ) antipsychotics. Moreover, psychostimulants, amphetamine (AMPH) or lisdexamfetamine (LSDX), were administered to NWR animals aiming to mimic the human first episode of psychosis, and the effects on serum lipids were also evaluated. Discrepancies in lipids between SHR and NWR animals, which included increased total lipids and decreased phospholipids in SHR compared with NWR, were similar to the differences previously reported for SCZ patients relative to healthy controls. Administration of psychostimulants in NWR decreased omega-3, which was also decreased in the first episode of psychosis of SCZ. Moreover, choline glycerophospholipids allowed us to distinguish the effects of CLZ in SHR. Thus, changes in the lipid metabolism in SHR seem to be reversed by the long-term treatment with the atypical antipsychotic CLZ, which was under the same condition described to reverse the SCZ-like endophenotypes of this validated animal model for SCZ. These data open new insights for understanding the potential influence of the treatment with typical or atypical antipsychotics on circulating lipids. This may represent an outcome effect from metabolic pathways that regulate lipids synthesis and breakdown, which may be reflecting a cell lipids dysfunction in SCZ.

1 June 2019 in Schizophrenia Research
Verified
Journal Article
Closed access
CMCaroline Dal Mas
Caroline Dal Mas
JNJoão Nani
João Nani
CNCristiano Noto
Cristiano Noto
CYCamila M. Yonamine
Camila M. Yonamine
GCGraccielle Rodrigues da Cunha
Graccielle Rodrigues da Cunha
MHMirian Hayashi
Mirian Hayashi

9 January 2020 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
JNJoão Nani
João Nani
MFMatheus Fonseca
Matheus Fonseca
SESheila A Engi
Sheila A Engi
MPMayara G Perillo
Mayara G Perillo
CDCarlos Sb Dias
Carlos Sb Dias
MHMirian Af Hayashi
Mirian Af Hayashi
Background: Interaction of nuclear-distribution element-like 1 with disrupted-in-schizophrenia 1 protein is crucial for neurite outgrowth/neuronal migration, and this interaction competitively inhibits nuclear-distribution element-like 1 peptidase activity. Nuclear-distribution element-like 1 activity is reduced in antipsychotic-naïve first-episode psychosis and in medicated chronic schizophrenia, with even lower activity in treatment-resistant schizophrenia. Aims: The purpose of this study was to investigate in a rat model overexpressing human non-mutant disrupted-in-schizophrenia 1, with consequent dysfunctional disrupted-in-schizophrenia 1 signaling, the relation of nuclear-distribution element-like 1 activity with neurodevelopment and dopamine-related phenotypes. Methods: We measured cell distribution in striatum and cortex by histology and microtomography, and quantified the basal and amphetamine-stimulated locomotion and nuclear-distribution element-like 1 activity (in blood and brain) of transgenic disrupted-in-schizophrenia 1 rat vs wild-type littermate controls. Results: 3D assessment of neuronal cell body number and spatial organization of mercury-impregnated neurons showed defective neuronal positioning, characteristic of impaired cell migration, in striatum/nucleus accumbens, and prefrontal cortex of transgenic disrupted-in-schizophrenia 1 compared to wild-type brains. Basal nuclear-distribution element-like 1 activity was lower in the blood and also in several brain regions of transgenic disrupted-in-schizophrenia 1 compared to wild-type. Locomotion and nuclear-distribution element-like 1 activity were both significantly increased by amphetamine in transgenic disrupted-in-schizophrenia 1, but not in wild-type. Conclusions: Our findings in the transgenic disrupted-in-schizophrenia 1 rat allow us to state that decreased nuclear-distribution element-like 1 activity reflects both a trait (neurodevelopmental phenotype) and a state (amphetamine-induced dopamine release). We thus define here a role for decreased nuclear-distribution element-like 1 peptidase activity both for the developing brain (the neurodevelopmental phenotype) and for the adult (interaction with dopaminergic responses), and present nuclear-distribution element-like 1 activity in a novel way, as unifying neurodevelopmental with dysfunctional dopamine response phenotypes.